Janssen announced on the 7th that it will be applied as a first-line treatment for patients with high-risk metastatic prostate cancer with hormone-responsiveness from the 1st.

Zytiga, as a CYP17 inhibitor, was approved by the MFDS in July 2012 as a treatment for metastatic castration-resistant prostate cancer, and added hormone-responsive high-risk metastatic prostate cancer treatment indications in June 2018.

With this amendment, Zytiga can be used in patients newly diagnosed with hormone-responsive high-risk metastatic prostate cancer (mHSPC). If two or more of the three conditions are satisfied, such as visceral metastasis (excluding lymph node metastasis), which can be confirmed by i